TNGX חוב לטווח קצר של החברה Tango Therapeutics Corp

Tango Therapeutics (TNGX) is developing immunotherapy-based cancer treatments while outsourcing all drug production to third-party contractors, leaving the company vulnerable amid fierce competition for clinical trial participants. This chart of the market value reflects the 0.00 indicator. Meanwhile, the business is protected by US law and remains insulated from the impact of international conflicts or trade restrictions.

Short-term debts reflect the total liabilities requiring repayment within one year. By analyzing debt with a maturity of up to one year, an investor assesses the company's liquidity and default risk. The stability of this metric confirms the effectiveness of working capital management. For Tango Therapeutics (TNGX), loan control is critical due to the capital intensity of cancer immunotherapy development. High research costs make the company dependent on the availability of external financing.